Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - farydak
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp18491093bf4c2b130ac9eb83b74183eb
identifier: http://ema.europa.eu/identifier
/EU/1/15/1023/001-003
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Farydak 10 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-18491093bf4c2b130ac9eb83b74183eb
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/15/1023/001-003
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - farydak
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What Farydak is Farydak is an anti-cancer medicine that contains the active substance panobinostat, which belongs to a group of medicines called pan-deacetylase inhibitors.
What Farydak is used for Farydak is used to treat adult patients with a rare type of blood cancer called multiple myeloma. Multiple myeloma is a disorder of plasma cells (a type of blood cell) that grow out of control in the bone marrow.
Farydak blocks the growth of cancerous plasma cells and reduces the number of cancer cells.
Farydak is always used together with two other medicines: bortezomib and dexamethasone.
If you have any questions about how Farydak works or why you have been given it, ask your doctor or pharmacist.
Do not take Farydak:
Warnings and precautions Follow all your doctor s instructions carefully.
Talk to your doctor or pharmacist before taking Farydak:
Tell your doctor or pharmacist straight away during treatment with Farydak:
Your doctor may need to change your dose, temporarily stop or completely stop your treatment with Farydak in case you experience side effects.
Monitoring during your treatment with Farydak You will have regular blood tests during treatment with Farydak. These are to:
Your heart rate will also be checked using a machine that measures the electrical activity of the heart (called an ECG).
Children and adolescents Farydak is not to be used in children or adolescents under 18 years of age.
Other medicines and Farydak Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription, such as vitamins or herbal supplements, because they might interact with Farydak.
In particular tell your doctor or pharmacist if you are taking any of the following medicines:
These medicines should be used with care or may need to be avoided during your treatment with Farydak. If you are taking any of these medicines, your doctor might prescribe a different medicine for you during your treatment with Farydak.
Ask your doctor or pharmacist if you are not sure whether your medicine is one of the medicines listed above.
During Farydak treatment, you should also tell your doctor or your pharmacist if you are prescribed another medicine that you have not already been taking.
Farydak with food and drink You should not eat star fruit, pomegranate or grapefruit or drink pomegranate or grapefruit juice during your treatment with Farydak, as they may increase the amount of the medicine that passes into your blood.
Pregnancy and breast-feeding Due to the potential risk of death or malformation to the foetus, Farydak should not be taken during:
Pregnancy Farydak should not be taken during pregnancy, unless the potential benefit to the mother is greater than the potential risk to the baby. If you are pregnant, think you might be pregnant or plan to become pregnant, ask your doctor for advice. Your doctor will discuss with you the possible risks of taking Farydak during pregnancy.
Breast-feeding You must not take Farydak if you are breast-feeding.
Contraception for women and men Due to the potential risk of death or malformation to the foetus, you should use the following methods of contraception while taking Farydak:
For women taking Farydak If you are a sexually active woman, you should have a pregnancy test before starting Farydak treatment and you must use a highly effective method of contraception during treatment with Farydak. You must also use this for three months after you have stopped taking Farydak. Your doctor will discuss with you which is the best method for you to use. If you use a hormonal contraceptive you must also use a barrier method of contraception (such as condom or diaphragm) in addition.
For men taking Farydak If you are a sexually active man, you should use condoms during treatment with Farydak. You should also do this for six months after you have stopped taking Farydak. If your partner is able to become pregnant she should also use a highly effective method of contraception during your treatment and for six months after. Tell your doctor straight away if your partner becomes pregnant while you are taking Farydak or during the six months following your treatment with Farydak.
Driving and using machines Farydak may have a minor influence on the ability to drive and use machines. If you feel dizzy while taking this medicine, do not drive a vehicle or use any tools or machines.
Always take this medicine exactly as your doctor has told you. Check with your doctor or your pharmacist if you are not sure.
How much to take
Cycles 1-8 (3-week cycles) Week 1 Days Week 2 Days Week 3 Farydak 1
3
5
8
Rest period Bortezomib 1
4
8
Rest period Dexamethasone 1 2
4 5
8 9
11 Rest period
Table 2 Recommended schedule for taking Farydak in combination with bortezomib and dexamethasone (cycles 9-16).
Cycles 9-(3-week cycles) Week 1 Days Week 2 Days Week 3 Farydak 1
3
5
8
Rest period Bortezomib 1
8
Rest period Dexamethasone 1 2
8 9
Rest period
Your doctor will tell you exactly how many capsules of Farydak you need to take. Do not change the dose without talking to your doctor.
Take Farydak once a day at the same time each day only on the scheduled days.
Taking this medicine
If you vomit after you swallow the Farydak capsules, do not take any more capsules until your next scheduled dose.
How to use the Farydak blister
One Farydak blister = 3 weeks = 1 cycle
The days of the cycle are numbered on the blister.
Take Farydak on days 1, 3 and 5 and on days 8, 10 and 12. Push the Farydak capsule through the pocket on days 1, 3 and 5 of week 1 and days 8, 10 and 12 of week 2. On days when you do not have to take Farydak, including the rest period in week 3, scratch the relevant empty cavities with your finger nail to help you keep track of your medicine schedule.
How long to take Farydak Keep taking Farydak for as long as your doctor tells you. This is a long-term treatment with 16 cycles (48 weeks). Your doctor will monitor your condition to see if the treatment is working. If you have questions about how long to take Farydak, talk to your doctor or pharmacist.
If you take more Farydak than you should If you accidentally take more capsules than you should, or if someone else accidentally takes your medicine, talk to a doctor or go to a hospital straight away. Take the pack and this leaflet with you. You may need medical treatment.
If you forget to take Farydak
Do not take a double dose to make up for a forgotten dose.
Never take a missed dose of Farydak on one of the off days when no Farydak dose is planned.
Tell your doctor about all the doses that you have missed during any 21-day cycle of treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects could be serious STOP taking Farydak and seek medical help immediately if you experience any of the following:
Tell a doctor or a pharmacist straight away if you notice any of these side effects:
Other possible side effects If any of the side effects below becomes severe, tell your doctor, or your pharmacist.
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
What Farydak contains
What Farydak looks like and contents of the pack Farydak 10 mg hard capsules are light green opaque capsules (15.6 16.2 mm) containing white to almost white powder, with radial marking LBH 10 mg in black ink on the cap and two radial bands in black ink on the body, provided in blisters. Farydak 15 mg hard capsules are orange opaque capsules (19.1 19.7 mm) containing white to almost white powder, with radial marking LBH 15 mg in black ink on the cap and two radial bands in black ink on the body, provided in blisters. Farydak 20 mg hard capsules are red opaque capsules (19.1 19.7 mm) containing white to almost white powder, with radial marking LBH 20 mg in black ink on the cap and two radial bands in black ink on the body, provided in blisters.
The following pack sizes are available: blister packs containing 6, 12 or 24 capsules.
Not all pack sizes may be marketed.
Marketing Authorisation Holder pharmaand GmbH Taborstrasse 1
1020 Wien Austria
Manufacturer Siegfried Barbera, S.L. 1 Ronda de Santa Maria, 08210 Barber del Vall s
Barcelona, Spain
This leaflet was last revised in
Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-18491093bf4c2b130ac9eb83b74183eb
Resource Composition:
Generated Narrative: Composition composition-en-18491093bf4c2b130ac9eb83b74183eb
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/15/1023/001-003status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - farydak
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp18491093bf4c2b130ac9eb83b74183eb
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp18491093bf4c2b130ac9eb83b74183eb
identifier:
http://ema.europa.eu/identifier
/EU/1/15/1023/001-003type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Farydak 10 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en